Inactive Instrument

Amarin Corporation plc (ADR) Share Price Xetra

Equities

EH3A

US0231112063

Biotechnology & Medical Research

Real-time Estimate Tradegate 06:27:07 24/06/2024 pm IST
0.653 EUR 0.00% Intraday chart for Amarin Corporation plc (ADR)

Financials

Sales 2024 * 202M 188M 16.87B Sales 2025 * 215M 200M 17.93B Capitalization 284M 264M 23.67B
Net income 2024 * -70M -65.22M -5.84B Net income 2025 * -64M -59.63M -5.34B EV / Sales 2024 * 1.19 x
Net cash position 2024 * 43.92M 40.92M 3.67B Net cash position 2025 * 159M 148M 13.24B EV / Sales 2025 * 0.58 x
P/E ratio 2024 *
-3.91 x
P/E ratio 2025 *
-4.15 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.48%
More Fundamentals * Assessed data

Latest transcript on Amarin Corporation plc (ADR)

Managers TitleAgeSince
Chief Executive Officer 61 01/12/01
Director of Finance/CFO 52 20/22/20
Compliance Officer 55 15/11
Members of the board TitleAgeSince
Director/Board Member 45 28/23/28
Chairman 49 28/23/28
Director/Board Member 66 28/23/28
More insiders
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
More about the company